

Special Issue

Nanocarriers in Vaccine Applications

Message from the Guest Editors

The discovery of vaccines is by far the most important medical invention in recent centuries and has contributed to the eradication of many diseases. Nanotechnology has been highlighted as an important contributor in vaccine development for adjuvants and delivery systems. The combination of emerging nanotechnologies and subunit vaccines has led to the foundation of effective and safe vaccine development. In recent years, the effective use of lipid nanoparticle-based mRNA COVID-19 vaccines in clinical settings has underlined the potential of nanotechnology in vaccine development. Nanocarriers enhance the bioavailability of the vaccine and act as adjuvants to stimulate a higher immune response (humoral and cell-mediated immune responses), increasing the vaccination's efficacy. The Special Issue's aim is to highlight the development of new vaccines and vaccines that have been improved using novel nanocarrier formulations, with a focus on preclinical and clinical evaluation. This issue will also include articles that provide critical reviews of current advancements and updates on nanocarrier-based vaccines from experts in relevant fields.

Guest Editors

Dr. Robin Kumar

Dr. Jairam Meena

Dr. Ruchika Dehinwal

Deadline for manuscript submissions

closed (30 October 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/136073

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).